EMA ’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as a monotherapy to treat adult patients with metastatic Mer …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Merck | Pfizer | Pharmaceuticals